- $106.34bn
- $123.47bn
- €46.72bn
Merck, rivals eye Inhibrx experimental cancer drug tied to Keytruda, sources say
Merck, rivals eye deal for Inhibrx experimental cancer drug tied to Keytruda, sources say
Roche submits multiple sclerosis drug fenebrutinib to regulators despite patient deaths (updated)
Brief: Sanofi's Tzield Approved In US To Delay Onset Of Stage 3 Type 1 Diabetes In Young Children
Brief: Sanofi: FDA Extends Target Action Date For Sarclisa Subcutaneous Review
Roche submits multiple sclerosis drug fenebrutinib to regulators despite patient deaths
US military no longer required to get flu vaccine, Hegseth says
Brief: Sanofi's Nuvaxovid Covid-19 Vaccine Showed Better Tolerability Than Mnexspike In Head-To-Head Study
Brief: DKSH And Sanofi Enter Strategic Partnership
Brief: Sanofi's Dupixent Approved In The EU As First Targeted Medicine For Young Children With CSU
Brief: Sanofi's COVID-19 Vaccine Nuvaxovid Authorised In Canada
Food giants strain to cut the corporate mustard: podcast
Shah Capital intends to vote against Novavax's board nominees, executive compensation (updated)
Shah Capital intends to vote against Novavax's board nominees, executive compensation
Brief: Sanofi/Lunsekimig: Exploratory Velvet Phase 2B Study Did Not Meet Its Primary Endpoint
Factbox: Global pharma companies that have publicly announced Trump drug pricing agreements
Focus: Drugmakers delay some European launches with a wary eye on Trump's pricing policies
Focus: Drugmakers delay some European launches with a wary eye on Trump's pricing policies
Brief: Sanofi’s Rezurock Approved In The EU To Treat Chronic Graft-vs-host Disease